The pulmonary microvasculature entraps induced vascular progenitor cells (iVPCs) systemically delivered after cardiac ischemia-reperfusion injury: Indication for preservation of heart function via paracrine effects beyond engraftment

Microcirculation : the Official Journal of the Microcirculatory Society, Inc
Melanie ZieglerKarlheinz Peter

Abstract

Stem cell-based regenerative therapies have been intensively studied with the aim to define an ideal cell type for the treatment of myocardial infarction. We tested systemically delivered, platelet-targeted induced vascular progenitor cells (iVPCs) to study their potential to salvage damaged myocardium after ischemia-reperfusion injury. Using a mouse model of ischemia-reperfusion injury, we tested the potential of platelet-targeted iVPCs (1 × 106 targ-iVPCs) compared to non-targ-iVPCs and a saline control. Bioluminescence imaging, echocardiography, and histological analyses were performed. Four weeks after ischemia-reperfusion injury, systemic delivery of targ-iVPCs led to reduced fibrosis and infarct size (PBS: 25.7 ± 3.9 vs targ-iVPC: 18.4 ± 6.6 vs non-targ-iVPC: 25.1 ± 3.7%I/LV, P < 0.05), increased neovascularization, and restored cardiac function (PBS: 44.0 ± 4.2 vs targ-iVPC: 54.3 ± 4.5 vs non-targ-iVPC: 46.4 ± 3.8%EF, P < 0.01). Cell tracking experiments revealed entrapment of intravenously injected iVPCs in the pulmonary microvasculature in both cell-treated groups. Systemic delivery of iVPCs after cardiac ischemia-reperfusion injury is limited by pulmonary entrapment of the cells. Nevertheless, targ-iVPCs reduced infar...Continue Reading

References

Apr 27, 2005·Circulation·Michael HofmannHelmut Drexler
Oct 4, 2005·American Journal of Physiology. Heart and Circulatory Physiology·Yaqin XuZequan Yang
Sep 15, 2007·The New England Journal of Medicine·Derek M Yellon, Derek J Hausenloy
Nov 26, 2008·Circulation Research·Massimiliano GnecchiVictor J Dzau
Mar 6, 2012·Cell Stem Cell·Sudhir H RanganathJeffrey M Karp
Mar 28, 2013·PloS One·Michael MildnerHendrik Jan Ankersmit
Dec 18, 2013·BMJ : British Medical Journal·Martin J HoogduijnJooske Ijzer
Jan 18, 2014·Circulation Research·Susmita Sahoo, Douglas W Losordo
Jan 30, 2015·Circulation Research·Sheila A FisherEnca Martin-Rendon
Apr 18, 2015·Stem Cell Research & Therapy·Parul Dixit, Rajesh Katare
Aug 9, 2015·Journal of Molecular and Cellular Cardiology·Hua Zhang, James E Faber
Apr 1, 2017·Nature Reviews. Cardiology·Roberto Bolli, Shahab Ghafghazi

❮ Previous
Next ❯

Citations

Mar 25, 2019·Cardiovascular Research·Melanie ZieglerKarlheinz Peter
Jul 14, 2020·Expert Opinion on Pharmacotherapy·Amit RoutPaul A Gurbel
Jun 18, 2020·International Journal of Molecular Sciences·Ju-Ro LeeByung-Soo Kim
Nov 28, 2018·The Journal of Physiological Sciences : JPS·Tomohiro MatsumotoHidemi Fujino
Feb 1, 2019·Microcirculation : the Official Journal of the Microcirculatory Society, Inc·Marianne Tare

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.